Vergoeding 2019-2023 voor ATC-subgroep L01FF : Pd-1/pd-l1-remmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022* | 2023* | |
|---|---|---|---|---|---|
| L01FF01 Nivolumab | 84.122.591 | 78.899.720 | 79.802.692 | 82.150.150 | 91.185.661 |
| L01FF02 Pembrolizumab | 162.003.957 | 210.678.696 | 253.310.316 | 265.703.184 | 257.357.383 |
| L01FF03 Durvalumab | 10.698.611 | 36.600.395 | 49.440.398 | 52.495.172 | 51.379.711 |
| L01FF04 Avelumab | 1.731.085 | 1.605.589 | 1.555.627 | 5.829.144 | 8.450.124 |
| L01FF05 Atezolizumab | 5.132.378 | 5.295.746 | 8.052.828 | 7.538.247 | 8.516.973 |
| L01FF06 Cemiplimab | . | . | 2.436.473 | 4.895.232 | 5.890.915 |
| Totaal | 263.688.622 | 333.080.147 | 394.598.334 | 418.611.129 | 422.780.768 |